Regulatory discoherence: The case of remdesivir; WTO TRIPS Waiver informals
Newsletter Edition #14
As some countries get closer to accessing vaccines to fight the pandemic, it also serves to think about the regulatory processes that make this possible.
In our analyses of the week we take a look back at the regulatory processes around Gilead’s remdesivir and what this tells us about the need for greater convergence among public health authorities.
Keep reading with a 7-day free trial